JJJaishree Jeyaraman

Jaishree Jeyaraman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jaishree Jeyaraman has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Immuno-silent polymer capsules encapsulating nanoparticles for bioimaging applications

    by Jaishree Jeyaraman, Anna Malecka, Poonam Billimoria, Akansha Shukla, Barsha Marandi, Poulam M. Patel, Andrew M. Jackson, Sri Sivakumar

    PEGylated polymer capsules encapsulating LaVO 4 :Tb 3+ , GdVO 4 :Tb 3+ , Gd 2 O 3 :Tb 3+ , GdF 3 :Tb 3+ , YVO 4 :Tb 3+ and iron oxide nanoparticles are promising new fluorescence, magnetic and magnetofluorescence imaging agents.


  • Targeted Stealth Polymer Capsules Encapsulating Ln3+-Doped LaVO4 Nanoparticles for Bioimaging Applications

    by Jaishree Jeyaraman, Akansha Shukla, Sri Sivakumar

    We report synthesis of targeted PEGylated polymer capsules encapsulating Stoke’s shift and upconverting LaVO4 nanoparticles by following a unique approach for bioimaging applications. First, LaVO4:Ln3+@silica (Ln3+= Tb3+, Eu3+, and Yb3+/Er3+) core-shell nanoparticles are prepared by sol-gel method followed by layer-by-layer assembly of polymers and PEGylation over core-shell particles. Second, removal of silica core facilitates the trapping of LaVO4:Ln3+ nanoparticles inside the PEGylated polymer capsules. Finally, capsules are surface modified with antibodies to target cancer cells. The nanoparticles-loaded polymer capsules are found to be internalized and biocompatible with various cells (e.g. HeLa, A498, H460, MCF-7, Schwann, L929, and IC-21) suggesting their applicability in different types of cells. In addition, the capsules modified with antibodies show more specific uptake suggesting their targeting ability by 3-fold for MCF-7 and 10-fold for H460 cancer cells. Moreover, the nanoparticles-loaded polymer capsules were internalized by HeLa cells via macropinocytosis mechanism. We observed localized bright Stoke’s shift (Tb3+ ions, λex = 488 nm) and upconversion (Er3+ ions, λex = 980 nm) green fluorescence from cells suggesting their potential use as targeted bioimaging agents. KEYWORDS: LaVO4, PEGylated polymer capsules, cell uptake mechanism, upconversion lanthanide ions, Ln3+ doped nanoparticles, bioimaging.


  • Bio-distribution and in vivo/in vitro toxicity profile of PEGylated polymer capsules encapsulating LaVO4:Tb3+nanoparticles for bioimaging applications

    by C. R. Dhanya, Jaishree Jeyaraman, P. A. Janeesh, Akansha Shukla, Sri Sivakumar, Annie Abraham

    Lanthanide-doped nanoparticles are being explored for bioimaging applications owing to their unique optical properties. However, their toxicity profiles have not been explored in detail at the in vivo level which is a pre-requisite for clinical use. To this end, we have investigated a detailed in vivo/in vitro toxicity profiling of PEGylated polymer capsules encapsulating LaVO4:Tb3+ nanoparticles. First, in vitro toxicity studies were carried out in L929 mouse fibroblast cells in which MTT assay, neutral red uptake (NRU) assay, LDH release, cell morphology; quantification of reactive nitrogen species (RNS), reactive oxygen species (ROS), lipid peroxidation level, caspase-3 activity, and apoptosis assay were also performed. Second, in vivo studies were carried out in Swiss Albino mice, which included biodistribution studies (6 h and 24 h), evaluation of hematological parameters, and toxicity marker enzyme levels (inflammation, oxidative stress, tissue infiltration, liver dysfunction, etc.), organ histology, and genotoxocity. The detailed investigation of toxicity at in vitro and in vivo levels indicates the biocompatibility of PEGylated polymer capsules encapsulating LaVO4:Tb3+ nanoparticles proving their suitability for bio-imaging applications.